Clinical Trials Browser

Phase 3 × Unknown × Bortezomib × Clear all

NCT01685814 2023-04-27

Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance

Phase 3 Unknown

Multiple Myeloma

NCT01554852 2018-06-11

Myeloma XI

Phase 3 Unknown

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03345303 2017-11-17

Bortezomib in Intrahepatic Cholangiocellular Carcinoma

Phase 3 Unknown

Gastrointestinal

Cholangiocarcinoma

NCT01449344 2017-03-07

(R-HAD)

Phase 3 Unknown

Recurrence, Lymphoma, Mantle-Cell

NCT01134484 2012-07-20

VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)

Phase 3 Unknown

Pathologic Complete Response, Multiple Myeloma